- Home
- ZION vs LEGN Comparison
ZION vs LEGN Comparison
Compare ZION & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZION
- LEGN
- Stock Information
- Founded
- ZION 1873
- LEGN 2014
- Country
- ZION United States
- LEGN United States
- Employees
- ZION N/A
- LEGN N/A
- Industry
- ZION Major Banks
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- ZION Finance
- LEGN Health Care
- Exchange
- ZION Nasdaq
- LEGN Nasdaq
- Market Cap
- ZION 7.4B
- LEGN 7.0B
- IPO Year
- ZION N/A
- LEGN 2020
- Fundamental
- Price
- ZION $49.22
- LEGN $27.78
- Analyst Decision
- ZION Hold
- LEGN Strong Buy
- Analyst Count
- ZION 20
- LEGN 13
- Target Price
- ZION $58.00
- LEGN $75.67
- AVG Volume (30 Days)
- ZION 1.7M
- LEGN 1.5M
- Earning Date
- ZION 04-21-2025
- LEGN 05-13-2025
- Dividend Yield
- ZION 3.50%
- LEGN N/A
- EPS Growth
- ZION 28.66
- LEGN N/A
- EPS
- ZION 5.12
- LEGN N/A
- Revenue
- ZION $3,106,000,000.00
- LEGN $728,303,000.00
- Revenue This Year
- ZION $8.93
- LEGN $65.96
- Revenue Next Year
- ZION $3.99
- LEGN $52.55
- P/E Ratio
- ZION $9.61
- LEGN N/A
- Revenue Growth
- ZION 6.44
- LEGN 112.46
- 52 Week Low
- ZION $39.32
- LEGN $29.27
- 52 Week High
- ZION $63.22
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- ZION 60.80
- LEGN 29.61
- Support Level
- ZION $48.64
- LEGN $30.25
- Resistance Level
- ZION $50.21
- LEGN $33.30
- Average True Range (ATR)
- ZION 1.05
- LEGN 1.78
- MACD
- ZION 0.58
- LEGN -0.57
- Stochastic Oscillator
- ZION 84.93
- LEGN 5.19
About ZION Zions Bancorporation N.A.
Zions Bancorporation is a regional us bank with core operations that span 11 states. The bank is headquartered in Salt Lake City and does business primarily in the Western and Southwestern United States. Zions primarily focuses on providing banking services to small and midsize businesses, with the bulk of its loans focused on commercial and commercial real estate lending.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.